ATIC is seeking expressions of interest from those with first-hand experience of type 1 diabetes to join our community engagement panel.
Drive the implementation of immunotherapy clinical trials throughout Australia and New Zealand
Work closely with the type 1 diabetes community across the research cycle, from trial development through recruitment to communication of...
Harmonise data collection and ensure linkage with national and international diabetes networks.
Train, equip and update clinicians, scientists and the wider community on the fundamentals of immunotherapy, as well as the latest...
Attract immunotherapy trials to Australasia through innovation: the discovery of improved biomarkers, development of new therapies, and facilitation of biosample...
Advocate for regulatory approval and government funding of immunotherapy treatments for type 1 diabetes.
ATIC researchers are trialling a new medication called IMCY-0098 to see whether it preserves pancreas function by dampening the immune attack on insulin-producing cells that occurs in people with type 1 diabetes.
Are you eligible to participate?
ATIC is seeking expressions of interest from members of the type 1 diabetes community who are interested in joining our Community Engagement Panel.
3rd seminar in the ‘Beyond Insulin: Innovative research in T1D prevention and cure’ seminar series
2nd seminar in the ‘Beyond Insulin: Innovative research in T1D prevention and cure’ seminar series
Introducing ATIC’s new seminar series ‘Beyond Insulin: Innovative research in T1D prevention and cure’. Join us for a new session each month!